High protein intake from meat can lead to calcium loss and harm bone health

As to how consuming animal or plant protein impacts bone composition, many studies have been published. Numerous studies have shown that compared to plant-based protein, animal-based protein weakens bones. According to several research, persons who consume a lot of meat are more likely to develop osteoporosis (thin bone tissue) and fractures.

Resorption and formation of new bone are constantly balanced in healthy bones. Resorption is the breakdown of old bone to be reabsorbed (modeling). Most individuals are aware of the significance of calcium and vitamin D in the development and maintenance of strong bones. However, a theory that protein altered the body's natural chemistry in such a way that too much calcium was being excreted in urine emerged based on past research.

In one of her recent Instagram posts, nutritionist Anjali Mukerjee shares how meat protein can impact bone health. She writes, A high protein diet, especially from animal sources, can lead to calcium loss and harm bone health.

Meat has a high phosphorous-to-calcium ratio which increases calcium excretion and can cause bone demineralization.

Consuming animal protein, especially red meat, can make the blood acidic and lead to calcium being removed from bones.

She further writes, Protein is important for bone health, but too much animal protein, especially red meat, can actually harm your bones. So we need to make sure to include dairy, fish, chicken, and plant-based sources of protein in your diet, and don't forget to balance it with plenty of fruits, vegetables, and whole grains.

Look at her post:

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Congress-Left Alliance 'Unholy', Joining BJP Like taking dip in Ganga: Tripura Chief Minister

Waiting for response to load...

The rest is here:
Bone Health: Is Eating Meat Healthy For Your Bones?

Where did my health go - A player after being grabbed once

Also known as The Boner, and the Bone OneBone KeeperSans hasn't been same after playing deepwoken...Health10000

(Regenerates 20 Health per second)

The Bone Keeper is a monster found in the Eternal Gale.

Bone Keepers are giant, humanoid creatures, with inhuman proportions, having extremely short legs and large arms. It has clearly clawed feet, with bone claws for hands. They sport a red & gold loincloth of sorts on their lower body and seemingly not having any clothes on their upper half. Their head also appears to be made out of bones or a bone-like material.

Bone Keepers are incredibly mobile and hard-hitting enemies. They are certainly a large difficulty step-up from the mobs found in Layer 1, however all of their attacks are well telegraphed and can be avoided with proper experience, though their damage yields greater punishment, were you to fail to avoid them.

Slash

Excerpt from:
Bone Keeper | Deepwoken Wiki | Fandom

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

Here is the original post:
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment

See the original post here:
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

ROCKVILLE, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its Q3 earnings call. The year-end cash position as of December 31, 2022 amounted to approximately $7.4 million. On January 11, 2023, the Company successfully closed a public offering of securities raising gross proceeds of $7.5 million and net proceeds of approximately $6.8 million after deduction of placement agent commission and transaction related expenses.

Originally posted here:
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals

Read the original:
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe

Original post:
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis

Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer

Original post:
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development

Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET

Originally posted here:
Novan to Present at the Virtual Investor 2023 Companies to Watch Event

MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC). This trial is conducted under a collaborative clinical research agreement entered between Oryzon and the Fox Chase Cancer Center (FCCC), under which FCCC will be conducting different collaborative combination clinical trials with iadademstat, with Oryzon providing funding, the drug and technical expertise.

View original post here:
ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome. Unpublished results from this study will be evaluated to support a potential Phase 3 clinical study and FDA agreement on a regulatory plan for approval which the Company may pursue.

Continued here:
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

PORTLAND, Ore., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, is pleased to announce that it has appointed Gary Zipfel to the Company’s Board of Directors (the “Board”), effective immediately.   The Company has also appointed William Simpson as an Advisor to the Board of Chalice Brands.

See the original post here:
Chalice Brands Announces New Appointment to Board of Directors

- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib -

See the article here:
Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy. The updated NRDL will take effect from March 1, 2023.

See original here:
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

Eascra to showcase Janus Base Nanomaterials (JBNs) in the Innovation category Eascra to showcase Janus Base Nanomaterials (JBNs) in the Innovation category

More here:
Eascra Biotech Selected as Finalist for 2023 SXSW Pitch

MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a $3 million milestone payment from its partner 2seventy bio as part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future. This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform.

See more here:
Medigene Receives $3 Million Milestone Payment from 2seventy bio

1 Growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year’s), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.

Continued here:
VIRBAC: Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the...

LOS ANGELES, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Boyd Quinnell, CPA, MBA, to the Trethera Board of Directors as an independent director. A veteran healthcare executive with over 30 years of experience in executive and financial leadership, Mr. Quinnell will also chair the Board’s Audit Committee.

Here is the original post:
Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors

GAITHERSBURG, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the publication of an article highlighting the Company’s AIM platform as a new immunotherapy approach for viral diseases in Frontiers in Medicine. The article, titled “AIM Platform: A New Immunotherapy Approach for Viral Diseases,” focuses on the ability of AIM nanoparticles, which direct T cell response by mimicking the dendritic cell function, to consistently expand T cell populations with effector memory, central memory and self-renewing stem like memory phenotype directed at peptide-antigens from Epstein-Barr virus (EBV), human T-lymphotropic virus type 1 (HTLV-1) and human papillomavirus (HPV). Furthermore, T cells generated with the AIM platform are highly polyfunctional and display substantial in vitro cytotoxic activity against respective targeted antigens.

Read more here:
NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases

Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023

Read the original:
Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease